Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1016-1020

  Attar, Eyal C ^a   Amrein, Philip C ^a   Fraser, James W ^a   Fathi, Amir T ^a   McAfee, Steven ^a   Wadleigh, Martha ^b   DeAngelo, Daniel J ^b   Steensma, David P ^b   Stone, Richard M ^b   Foster, Julia ^a   Neuberg, Donna ^b   Ballen, Karen K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bortezomib and lenalidomide in MDS and AML

Indexed keywords

BORTEZOMIB; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; DESQUAMATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPOTENSION; HYPOXIA; INFECTION; KIDNEY FAILURE; LUNG INFILTRATE; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

BORTEZOMIB AND LENALIDOMIDE IN MDS AND AML;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRAZINES; REMISSION INDUCTION; SURVIVAL RATE; THALIDOMIDE;

EID: 84880944427     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.05.011     Document Type: Article

References (19)

1. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
2. Raza A., Reeves J.A., Feldman E.J., Dewald G.W., Bennett J.M., Deeg H.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 111:86-93.
3. Tehranchi R., Woll P.S., Anderson K., Buza-Vidas N., Mizukami T., Mead A.J., et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010, 363:1025-1037.
4. Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107:1156-1165.
5. Liesveld J.L., Rosell K.E., Bechelli J., Lu C., Messina P., Mulford D., et al. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest 2011, 29:439-450.
6. Alimena G., Breccia M., Musto P., Cilloni D., D'Auria F., Latagliata R., et al. Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. Leuk Res 2011, 35:504-507.
7. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
8. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002, 99:16220-16225.
9. Attar E.C., De Angelo D.J., Supko J.G., D'Amato F., Zahrieh D., Sirulnik A., et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008, 14:1446-1454.
10. Attar E.C., Johnson J.L., Amrein P.C., Lozanski G., Wadleigh M., Deangelo D.J., et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (alliance) study 10502. J Clin Oncol 2013, 31:923-929.
11. Oliva E.N., Cuzzola M., Aloe Spiriti M.A., Poloni A., Lagana C., Rigolino C., et al. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Acta Haematol 2013, 92:25-32.
12. Swerdlow S., Campo E., Harris N., Jaffe E., Pileri S., Stein H., et al. WHO Classification of Tumours of Haematopioetic and Lymphoid Tissues 2008, International Agency for Research on Cancer (IARC), Lyon. F. Bosman, E. Jaffe, S. Lakhani, H. Ohgaki (Eds.).
13. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
14. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
15. Richardson P.G., Weller E., Jagannath S., Avigan D.E., Alsina M., Schlossman R.L., et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009, 27:5713-5719.
16. Richardson P.G., Weller E., Lonial S., Jakubowiak A.J., Jagannath S., Raje N.S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
17. Chen Y., Kantarjian H., Estrov Z., Faderl S., Ravandi F., Rey K., et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk 2012, 12:341-344.
18. Fehniger T.A., Uy G.L., Trinkaus K., Nelson A.D., Demland J., Abboud C.N., et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011, 117:1828-1833.
19. Blum W., Klisovic R.B., Becker H., Yang X., Rozewski D.M., Phelps M.A., et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010, 28:4919-4925.